Experience with long-term glucocorticoid treatment in congenital adrenal hyperplasia: Growth pattern compared with genetic height potential

Journal of Pediatric Endocrinology and Metabolism

Volumn 19, Issue 3, 2006, Pages 245-251

  Aycan, Zehra ^a,c   Ocal, Gonul ^b   Berberoglu, Merih ^b   Cetinkaya, Ergun ^a   Adiyaman, Pelin ^b   Evliyaoglu, Olcay ^a  

^a KIRIKKALE UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c NONE   (Turkey)

Author keywords

Congenital adrenal hyperplasia; Height development

Indexed keywords

ALDOSTERONE; CORTICOTROPIN; FLUDROCORTISONE; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYPROGESTERONE; POTASSIUM; PRASTERONE SULFATE; RENIN; SODIUM; TESTOSTERONE;

ADOLESCENT; AGE; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BONE AGE; CHILD; CHILD DEVELOPMENT; CHILD GROWTH; CLINICAL ARTICLE; CONGENITAL ADRENAL HYPERPLASIA; CONTROLLED STUDY; DOSE RESPONSE; EXPERIENCE; FEMALE; FOLLOW UP; GROWTH RETARDATION; HEREDITY; HUMAN; INDIVIDUALIZATION; LONG TERM CARE; LONGITUDINAL STUDY; LOW DRUG DOSE; MALE; MATHEMATICAL COMPUTING; PATIENT MONITORING; PREDICTION; SCORING SYSTEM; STANDARD; TREATMENT OUTCOME;

EID: 33645541872     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2006.19.3.245     Document Type: Article

References (23)

1. Brook CGD, Zachmann M, Prader A, Murset G. Experience with long-term therapy in congenital adrenal hyperplasia. J Pediatr 1974; 85: 12-19.
2. Merke D, Bornstein SR, Avila NA, Chrousos GP. Future directions in the study and management of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Ann Intern Med 2002; 136: 320-334.
3. White PC, Speiser PW. Long-term consequences of childhood onset congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2002; 16: 273-288.
4. Labarta JI, Bello E, Ruiz-Echarri M, Rueda C, Martul P, Mayayo E, Ferrández Longás A. Childhood-onset congenital adrenal hyperplasia: Long-term outcome and optimization of therapy. J Pediatr Endocrinol Metab 2004; 17: 411-422.
5. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21: 245-291.
6. Mehls O, Tönshoff B, Kovacs G, Mayer C, Schurek J, Oh J. Interaction between glucocorticoids and growth hormone. Acta Paediatr 1993; 388: 77-82.
7. Stewart PM, Toogood AA, Tomlinson JW. Growth hormone, insulin-like growth factor-1 and the cortisol-cortisone shuttle. Horm Res 2001; 56: 1-6.
8. Mauras N. Growth hormone therapy in the glucocorticosteroid-dependent child: Metabolic and linear growth effects. Horm Res 2001; 56: 13-18.
9. Tönshoff B, Mehls O. Interaction between glucocorticoids and the somatotrophic axis. Acta Paediatr 1996; 417: 72-75.
10. Miell JP, Buchanan CR, Norman MR, Maheshwari GH, Blum WF. The evolution of changes in immunoreactive serum insulin like growth factors (IGFs), IGF-binding proteins, circulating growth hormone (GH) and GH-binding protein as a result of short-term dexamethasone treatment. J Endocrinol 1994; 142: 547-554.
11. Gourmelen M, Girard F, Binoux M. Serum somatomedin/insulin-like growth factor (IGF) and IGF carrier levels in patients with Cushing's syndrome or receiving glucocorticoid therapy. J Clin Endocrinol Metab 1982; 54: 885-892.
12. Allen DB, hoffman GL, Fitzpatrick P, Laessig R, Maby S, Slyper A. Improved precision of newborn screening for congenital adrenal hyperplasia using weight-adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr 1996; 130: 128-133.
13. Greulich WW, Pyle SI. Radiographic Atlas of Skeletal Development of the Hand and Wrist, 2nd Ed. Stanford, CA: Stanford University Press, 1959.
14. Girgis R, Winter JSD. The effects of glucocorticoid therapy on growth, bone mineral density, and bone turnover markers in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1997; 82: 3926-3929.
15. Bode HH, Rivkees SA, Cowley DM, Pardy K, Johnson S. Home monitoring of 17 hydroxyprogesterone levels in congenital adrenal hyperplasia with filter paper blood samples. J Pediatr 1999; 134: 185-189.
16. Neyzi O, Binyildiz P, Alp H. Turk cocuklarinin persentil buyume egrileri (0-17 yas). İst Tip Fak Mecm 1978; 41 (Suppl 74).
17. Cianfarani S, Geremia C, Germani D, Scire G, Maiorana A, Boemi S. Insulin resistance and insulin-like growth factor in children with intrauterine growth retardation. Is catch-up growth a risk factor? Horm Res 2001; 55 (Suppl 1): 7-10.
18. Jääskeläinen J, Voutilainen R. Growth of patients with 21-hydroxylase deficiency: An analysis of the factors influencing adult height. Pediatr Res 1997; 41: 30-33.
19. Savage MO, Lebrethon MC, Blair JC, Ho JTF, Johnston LB, Lienhardt A, Clark AJL, Chaussain JL. Growth abnormalities associated with adrenal disorders and their management. Horm Res 2001; 56: 19-23.
20. Silva IN, Kater CE, Cunha CF, Viana MB. Randomized controlled trial of growth effect of hydrocortisone in congenital adrenal hyperplasia. Arch Dis Child 1997; 77: 214-218.
21. Knorr D, Hinrichsen de Lienau SGC. Persistent obesity and short final height after corticoid overtreatment for congenital adrenal hyperplasia (CAH) in infancy. Acta Paediatr Jpn 1988; 30: 89-92.
22. Hargiati G, Solyom J, Battelino T, Lebl J, Pribilincova Z, Hauspie R, Kovacs J, Waldhauser F, Frisch H, MEWPE-CAH study group. Growth patterns and final height in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res 2001; 55: 161-171.
23. New MI, Gertner JM, Chir B, Speiser PW, del Balzo P. Growth and final height in classical and nonclassical 21-hydroxylase deficiency. Acta Paediatr Jpn 1988; 30: 79-88.